Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGN-242071 in Mild to Moderate Alzheimer's Disease
NCT03316898Phase 1Withdrawn
- Sponsor
- Allergan
- Start
- Sep 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HTL0018318 in Alzheimer's disease (AD) (4 arms), sponsored by Allergan. Primary endpoints: Change from Baseline in Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Metabolic Measure of Standard Uptake Value Ratio (SUVR) at Day 28, Percentage of Participants with Treatment-Emergent Adverse Events at Day 35 and 8 more. Planned start Sep 2018; status: withdrawn.
02
Drugs
HTL0018318
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03316898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03316898.